Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



Hansoh Pharmaceutical Group Company Limited 翰森製藥集團有限公司

(Incorporated in the Cayman Islands with limited liability)
(Stock Code: 3692)

VOLUNTARY ANNOUNCEMENT

CLINICAL TRIAL NOTICE OF "HS-10516 CAPSULES"

The board of directors (the "Board") of Hansoh Pharmaceutical Group Company Limited (the "Company" and together with its subsidiaries, the "Group") is pleased to announce that "HS-10516 Capsules" (license-in as NKT2152, the "Product"), a Category 1 innovative drug, has been granted a clinical trial notice issued by the National Medical Products Administration of the People's Republic of China, and is intended to be used for the treatment of renal cell carcinoma (RCC).

ABOUT HS-10516 (NKT2152)

HS-10516 is a small molecule that inhibits HIF-2α. As disclosed in the announcement of the Company dated May 3, 2022, Hansoh (Shanghai) Healthtech Company Limited* (翰森(上海)健康科技有限公司) and Jiangsu Hansoh Pharmaceutical Group Company Limited* (江蘇豪森藥業集團有限公司), both wholly-owned subsidiaries of the Company, obtained an exclusive license from NiKang Therapeutics Inc. to develop and commercialize the Product in the People's Republic of China (including Hong Kong, Macau and Taiwan).

By Order of the Board **Hansoh Pharmaceutical Group Company Limited Zhong Huijuan**Chairlady

Hong Kong, June 13, 2023

As at the date of this announcement, the Board comprises Ms. Zhong Huijuan as chairlady and executive director, Mr. Lyu Aifeng and Ms. Sun Yuan as executive directors, and Mr. Lin Guoqiang, Mr. Chan Charles Sheung Wai and Ms. Yang Dongtao as independent non-executive directors.

* for identification purposes only